Oxymetholone in aplastic anaemia

羟甲烯龙治疗再生障碍性贫血

阅读:1

Abstract

Thirty-one patients with aplastic anaemia were treated with oxymetholone. Twenty-eight patients lived beyond 2 months and of these eleven patients showed clinical and haematological improvement. Ten of these had some active erythropoietic areas as shown by bone marrow biopsies and by the presence of an elevated reticulocyte count in the peripheral blood. Two patients who responded in spite of a markedly hypoplastic marrow and reticulocytopenia became oxymetholone dependent and relapsed when the drug was withdrawn. They failed to respond a second time when oxymetholone was re-introduced. Side effects were frequent. These were mostly tolerable and reversible on reduction of the dose but three patients died of acute myeloblastic leukaemia and in three others the drug had to be withdrawn.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。